Anastrozole: all 149 studies that test it
Page 2 of 2. Open to participants first (15), then studies with results posted, then the rest; newest registration first within each.
- Study of Arimidex and Radiotherapy SequencingStatus unknownNCT01402193Phase 3
- MK2206 in Combination With Anastrozole, Fulvestrant, or Anastrozole and Fulvestrant in Treating Postmenopausal Women With Metastatic Breast CancerCompletedNCT01344031Phase 1
- Fulvestrant (F)/Goserelin (G) vs Anastrozole (A)/G vs G for Premenopausal WomenStatus unknownNCT01266213Phase 2
- Randomized Phase II Trial of Anastrozole Plus Metronomic Tegafur-uracil as Neo-adjuvant Therapy in Postmenopausal Breast CancerTerminatedNCT01262274Phase 2
- Bioavailability Study of Anastrozole Tablets 1 mg of Dr.Reddy's Under Fed ConditionsCompletedNCT01155960Phase 1
- Bioavailability Study of Anastrozole Tablets 1 mg of Dr.Reddy's Under Fasting ConditionsCompletedNCT01155947Phase 1
- Bioequivalency Study of Anastrozole 1 mg Under Fasted ConditionsCompletedNCT01155102Not applicable
- Bioequivalency Study of Anastrozole 1 mg Under Fed ConditionsCompletedNCT01155089Not applicable
- Anastrozole Reduced Proliferation and Progesterone Receptor Indexes in Short Term Hormone TherapyCompletedNCT01016665Not applicable
- Metabolic Effects of Steroids in Obese MenStatus unknownNCT00983554Not applicable
- Study of Faslodex With or Without Concomitant Arimidex Versus Exemestane Following Progression on Non-steroidal Aromatase Inhibitors (NSAI)CompletedNCT00944918Phase 3
- Letrozole, Anastrozole, Exemestane, or Tamoxifen Citrate in Treating Postmenopausal Women With Breast CancerCompletedNCT00893061Phase 3
- STARS Breast Trial (Study of Anastrozole and Radiotherapy Sequencing)Status unknownNCT00887380Phase 3
- ATAC - Arimidex, Tamoxifen Alone or in CombinationCompletedNCT00849030Phase 3
- ATAC - Endometrial Sub-ProtocolCompletedNCT00814125Phase 3
- ATAC - Bone Density Sub-ProtocolCompletedNCT00784940Phase 3
- ATAC - Pharmacokinetics (PK) Sub-ProtocolCompletedNCT00784862Phase 3
- ATAC - Quality of Life Sub-ProtocolCompletedNCT00784680Phase 3
- Pre-operative Hormonal Treatment for Hormone Receptor Positive Breast CancerSuspendedNCT00738777Phase 2
- Regulation of Cortisol Metabolism and Fat PatterningStatus unknownNCT00694733Not applicable
- Fulvestrant With or Without Lapatinib and/or Aromatase Inhibitor Therapy in Treating Postmenopausal Women With Metastatic Breast Cancer That Progressed After Previous Aromatase Inhibitor TherapyStatus unknownNCT00688194Phase 3
- Gynecomastia Extension StudyCompletedNCT00637182Phase 3
- Efficacy of Anastrozole and Fulvestrant in Patients With ER Positive, HER2 Negative, Operable Breast CancerCompletedNCT00629616Phase 2
- Gene Expression Following Short Term Exposure to Neoadjuvant Endocrine Therapy in Invasive Breast CancerCompletedNCT00588003Phase 1
- A Prospective,Open-label Study of Anastrozole in Post-menopausal Women With Hormone Sensitive Advanced Breast CancerCompletedNCT00544986Phase 4
- Study of Anastrozole, Letrozole, or Exemestane With or Without Tamoxifen in Treating Postmenopausal Women With Hormone-Responsive Breast Cancer That Has Been Completely Removed By SurgeryStatus unknownNCT00541086Phase 3
- Partial Double-Blind, Placebo-Controlled Study to Assess the Effect of Anastrozole on the Endometrium in Healthy VolunteersCompletedNCT00467493Phase 2
- Effect of Increasing Testosterone on Insulin Sensitivity in Men With the Metabolic SyndromeTerminatedNCT00438321Phase 1
- Neoadjuvant Hormonal Treatment of Postmenopausal Women Who Have Operable Breast CancerCompletedNCT00437853Not applicable
- Antiestrogen vs Aromatase Inhibitor After Adjuvant Chemotherapy for Breast CancerTerminatedNCT00437359Phase 2
- Insulin Sensitivity in Men With the Metabolic SyndromeSuspendedNCT00433173Not applicable
- Different Durations of Adjuvant Anastrozole Therapy After 2 to 3 Years Tamoxifen Therapy in Breast CancerCompletedNCT00301457Phase 3
- 3 Years of Anastrozole vs. no Treatment as Extended Adjuvant Therapy for Postmenopausal Women With Breast CancerCompletedNCT00300508Phase 3
- ABCSG 8 - Adjuvant Treatment in Patients With Hormone Receptor-positive Breast Cancer With Good to Moderate Differentiation.CompletedNCT00291759Phase 3
- Effectiveness of Combination of Arimidex and Nolvadex in Adjuvant Therapy of Breast Carcinoma in Postmenopausal Women.CompletedNCT00287534Phase 2
- ITA - Clinical Study Comparing ARIMIDEX™ With NOLVADEX™ in Women With Breast Cancer Treated With NOLVADEX for at Least 2 YearsCompletedNCT00286117Phase 3
- Anastrozole in Treating Postmenopausal Women With DCIS or Stage I-III Breast CancerCompletedNCT00244959Phase 2
- Open Label Arimidex in GynecomastiaCompletedNCT00241436Phase 2
- PROACT - Pre-Operative Arimidex Compared To TamoxifenCompletedNCT00232661Phase 3
- S0511, Goserelin and Anastrozole in Treating Men With Recurrent or Metastatic Breast CancerWithdrawnNCT00217659Phase 2
- Iressa (ZD1839) Plus Anastrozole (Arimidex) in Patients With Ovarian CancerCompletedNCT00181688Phase 2
- Arimidex Multicenter Trial in Growth Hormone (GH) Deficient BoysCompletedNCT00133354Phase 2/3
- Exemestane Versus Anastrozole as First Line Hormone Therapy in Postmenopausal Metastatic Breast Cancer PatientsCompletedNCT00128843Phase 2
- Anastrozole Biphosphonate Study in Postmenopausal Women With Hormone-Receptor-Positive Early Breast CancerCompletedNCT00082277Phase 4
- Anastrozole in Preventing Breast Cancer in Postmenopausal Women at Increased Risk of Breast CancerCompletedNCT00078832Phase 3
- Adjuvant Radiation Therapy Compared With Observation After Surgery in Treating Women With Estrogen Receptor Positive or Progesterone Receptor Positive Ductal Carcinoma In Situ of the Breast Who Are Receiving Tamoxifen or AnastrozoleStatus unknownNCT00077168Phase 2
- Comparing Anastrozole-Placebo to the Combination Anastrozole-ZD1839 in Postmenopausal Patients With Estrogen Receptor and/or Progesterone Receptor Metastatic Breast CancerCompletedNCT00077025Phase 2
- Arimidex in McCune Albright SyndromeCompletedNCT00055302Phase 2
- Anastrozole and ZD 1839 in Treating Postmenopausal Women With Metastatic Breast CancerCompletedNCT00049062Phase 2